Abstract: A method for immunizing a subject in need thereof against Neisseria gonorrhoeae by administering an immunogenic composition comprising meningococcal outer membrane vesicles (OMVs).

Abstract: Agents, kits, and methods that utilize oxygenation to prevent and/or treat intestinal inflammation and/or infections caused by anaerobic microorganisms are provided. In several embodiments, the formulations are provided as a capsule within a capsule in order to separate an oxygen prodrug from a catalyst until the formulation is at a target site within the intestine. In several embodiments, the catalyst is provided in an excess of the oxygen prodrug. In several embodiments, the prodrug is within an inner capsule or coating and a biological material comprising a catalyst (e.g., yeast, spirulina, chlorella, etc.) surrounds the encapsulated prodrug and the biological material is within a capsule or coating. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.

Abstract: The present invention relates to a method for biologically producing, from seaweeds, 3,6-anhydro-L-galactitol (L-AHGol) which is a novel sugar alcohol, and agarobititol (ABol) which is in a disaccharide form having 3,6-anhydro-L-galactitol (L-AHGol) as a reducing end, by using a genetic engineering technique in GRAS strains.

Abstract: Compositions and methods for treatment and prevention of vaginal infections where the compositions include creatinine, such as protonated creatinine or creatinine salts, and optionally one or more weak acids, such as boric acid. The compositions may be used to treat and/or prevent a vaginal infection, such as bacterial vaginosis, to prevent recurrence of a vaginal infection, to treat and/or prevent a sexually transmitted disease (STD) or sexually transmitted infection (STI), and reduce the incidence and/or risk of a subject transmitting a STI or STD.

Abstract: The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.

Abstract: The present disclosure relates generally to polypeptides, which may be used of the treatment of neurological diseases or disorders.

Abstract: A system and method for incubating a nutrient spore composition to at least begin the germination process at a point-of-use for small-scale farm applications. The composition comprises solid or powdered L-amino acids, a buffer, optionally D-glucose and/or D-fructose, optionally potassium, and Bacillus spores in a pre-measured filter packet. The method comprises adding a small amount of hot water in a temperature range of 60° C. to 80° C. to the filter packet for an incubation period of around 2 to 60 minutes to form an incubated bacteria solution that is discharged to a farm application. A drip-style coffee maker or similar system may be used to add hot water to the filter packet. The incubated bacteria solution is dispensed to animal drinking water, plants/crops, or an aquaculture pond.

Abstract: A Histomonas meleagridis strain having at least one of the following attenuating features (a) an inactivation of a gene, wherein the gene has the sequence identified by SEQ ID NO: 1 or a sequence with at least 90% sequence identity thereto, (b) an inactivation of a gene, wherein the gene has the sequence identified by SEQ ID NO: 2 or a sequence with at least 90% sequence identity thereto, (c) a truncating mutation in the coding sequence of a gene, wherein the gene has the unmutated coding sequence identified by SEQ ID NO: 3 or an unmutated coding sequence with at least 95% sequence identity thereto, and (d) a truncating mutation in the coding sequence of a gene, wherein the gene has the unmutated coding sequence identified by SEQ ID NO: 4 or an unmutated coding sequence with at least 95% sequence identity thereto. An anti-histomonosis vaccine containing the strain.

Abstract: The present invention relates to a mutant of Argonaute protein lacking a DNA cleavage activity but having a DNA binding activity, wherein the mutation of the mutant is located in a PIWI domain. The present invention also relates to a use based on the protein mutant, especially in enrichment of a target DNA and construction of sequence libraries. Therefore, the present invention also relates to a method for enrichment of a target DNA, comprising the following steps: (a) designing a guide sequence for a specific sequence in the target DNA; (b) binding the mutant according to the present invention, the guide sequence and the target DNA to obtain a mutant-guide sequence-target DNA ternary complex; (c) capturing the mutant-guide sequence-target DNA ternary complex through a capture medium; and (d) separating the target DNA from the captured mutant-guide sequence-target DNA ternary complex to obtain an enriched target DNA.

Abstract: Individuals consuming a prebiotic and who displayed improvements in blood glucose and/or insulin levels also displayed a decrease in the levels of the non-butyrate-producing Firmicutes genus of bacteria Sporacetigenium. Increasing levels of butyrate-producing Firmicutes genera were not consistently correlated with improvements in metabolism in response to prebiotic consumption. In the general population, Sporacetigenium levels are positively correlated with insulin levels.

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract: Described herein are methods of determining the efficacy of a candidate tuberculosis vaccine and methods of determining the efficacy of a candidate small organic molecule tuberculosis treatment by administering the candidate tuberculosis vaccine or the small organic molecule tuberculosis treatment to an animal which has been infected with an auxotrophic Mycobacterium. The auxotrophic Mycobacterium has a mycobacterial genome in which (i) argB gene, or a gene encoding a mycobacterial ArgB enzyme, has been fully or partially deleted and (ii) metA gene, or a gene encoding a mycobacterial MetA enzyme, has been fully or partially deleted, wherein the Mycobacterium is sterilized in the absence of arginine and methionine). The methods include quantifying the amount of auxotrophic Mycobacterium to determine the efficacy.

Abstract: A monoclonal antibody may have a binding domain that binds to a peptide of the HTT protein having the sequence of p7543 (SEQ ID No. 3). Such a monoclonal according may include a heavy chain variable region CDR1 comprising GYTFTEYT (SEQ ID No. 66), a heavy chain variable region CDR2 comprising INPNNGGT (SEQ ID No. 67), a heavy chain variable region CDR3 comprising ASLDGRDY (SEQ ID No. 68), a light chain variable region CDR1 comprising QSLLNSRTRKNY (SEQ ID No. 69), a light chain variable region CDR2 comprising WAS (SEQ ID No. 70), and/or a light chain variable region comprising KQSYNLLT (SEQ ID No. 71).

Abstract: The present disclosure is the first to identify a host cell protein and its function with which MPT63 and MPT64, secreted antigens of Mycobacterium tuberculosis, interact, and to construct a recombinant MPT protein including each domain of MPT63 and MPT64 interacting with the host cell protein, and the recombinant MPT protein may be applied to a use for the prevention and treatment of tuberculosis by confirming that the recombinant MPT protein targets the Mycobacterium tuberculosis-infected macrophages and increases the ROS level and inflammatory cytokine expression in macrophages, thereby inducing the death of Mycobacterium tuberculosis. And MPT protein of the present disclosure can improve the vaccine effect by the BCG vaccine so that it can be used as a tuberculosis vaccine and/or vaccine adjuvant either alone or together with known tuberculosis vaccines.

Abstract: There is provided novel peptides for use in diagnosis of CagA+ H. pylori infection or the prediction of risk for gastric cancer. The peptides bind antibodies from CagA+ H. pylori patients with high specificity and sensitivity, and can be used for example in a diagnostic kit.

Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.

Abstract: Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).

Abstract: Provided are SpdE polypeptides and variants and nucleic acids encoding the SpdE polypeptides and variants. Also provided are vectors including one or more nucleic acids encoding a SpdE polypeptide or variant and cells including a nucleic acid encoding the SpdE polypeptide or variant, as well as cells expressing a SpdE polypeptide or variant and compositions including such cells and a pharmaceutically acceptable carrier. Finally, methods of detecting presence and/or amount of one or more amino acids in a sample are provided. The methods include contacting the sample with a SpdE protein, measuring diguanylate cyclase activity of the SpdE protein; and comparing the diguanylate cyclase activity of the SpdE protein to a control. The methods can utilize isolated SpdE protein or a cell expressing a SpdE protein.

Abstract: The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.

Abstract: The present invention relates to the field of recombinant protein production in a host cell. More specifically the invention relates to the field of oral protein delivery. Specifically, the invention provides oral pharmaceutical formulations comprising the culture medium of a recombinant host secreting a recombinant protein. The resulting oral pharmaceutical formulations are useful for the treatment of gastro-intestinal and/or buccal disorders. Additionally, the oral pharmaceutical formulations are useful for prophylactic and vaccine purposes.